News & blog

Drug discovery firm’s leukaemia treatment breakthrough

DRUG discovery and development company Redx Pharma has unveiled a major breakthrough in treatment for leukaemia and other blood cancers.

The listed company, based at Alderley Park in Cheshire, says it has reached pre-clinical proof of concept on a reversible BTK inhibitor, which offers “exciting potential” to treat Chronic Lymphocytic Leukaemia (CLL), one of the most common types of leukaemia in adults, not usually curable.

BTK (Bruton’s Tyrosine Kinase) is an important enzyme in the B-cell receptor signalling pathway and is implicated in blood cancers such as CLL.

Chief executive Neil Murrary said: “We are delighted to announce we have reached pre-clinical proof of concept for an oncology lead that has the potential to treat leukaemia and other blood cancers. Read More